<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Wurster</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Hummel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Richter</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">Christian-Albrechts University Kiel</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Giefing</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">Christian-Albrechts University Kiel</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">Polish Academy of Sciences</orgName>
								<address>
									<settlement>Poznan</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Hartmann</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Dr Senckenberg Institute of Pathology</orgName>
								<orgName type="department" key="dep2">Medical School</orgName>
								<orgName type="institution">University of Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M-L</forename><surname>Hansmann</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Dr Senckenberg Institute of Pathology</orgName>
								<orgName type="department" key="dep2">Medical School</orgName>
								<orgName type="institution">University of Frankfurt</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Kreher</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Köchert</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Krappmann</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Research Unit Cellular Signal Integration</orgName>
								<orgName type="institution" key="instit2">Helmholtz Zentrum München für Gesundheit und Umwelt</orgName>
								<address>
									<settlement>Neuherberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution" key="instit1">Haematopathology Section and Lymph Node Registry</orgName>
								<orgName type="institution" key="instit2">Christian-Albrechts University Kiel</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charité-Universitätsmedzin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S-S</forename><surname>Wenzel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Lenz</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Division of Translational Oncology</orgName>
								<orgName type="department" key="dep2">Department of Medicine A</orgName>
								<orgName type="department" key="dep3">Cluster of Excellence EXC 1003</orgName>
								<orgName type="department" key="dep4">Cells in Motion</orgName>
								<orgName type="institution">University Hospital Münster</orgName>
								<address>
									<settlement>Münster</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Janz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Dörken</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">Christian-Albrechts University Kiel</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">University Hospital Ulm</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">S</forename><surname>Mathas</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Max-Delbrück-Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Hematology, Oncology and Tumor Immunology</orgName>
								<address>
									<addrLine>Robert-Rössle-Straße 10</addrLine>
									<postCode>D-13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">9F8D2D1580EE2DE599345439497C5AD5</idno>
					<idno type="DOI">10.1038/leu.2016.238</idno>
					<note type="submission">Received 19 January 2016; revised 2 August 2016; accepted 9 August 2016; accepted article preview online 19 August 2016; advance online publication, 14 October 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:17+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Apart from its unique histopathological appearance with rare tumor cells embedded in an inflammatory background of bystander cells, classical Hodgkin lymphoma (cHL) is characterized by an unusual activation of a broad range of signaling pathways involved in cellular activation.</s><s>This includes constitutive high-level activity of nuclear factor-κB (NF-κB), Janus kinase/signal transducer and activator of transcription (JAK/STAT), activator protein-1 (AP-1) and interferon regulatory factor (IRF) transcription factors (TFs) that are physiologically only transiently activated.</s><s>Here, we demonstrate that inactivation of the putative ubiquitin E3-ligase PDLIM2 contributes to this TF activation.</s><s>PDLIM2 expression is lost at the mRNA and protein levels in the majority of cHL cell lines and Hodgkin and Reed-Sternberg (HRS) cells of nearly all cHL primary samples.</s><s>This loss is associated with PDLIM2 genomic alterations, promoter methylation and altered splicing.</s><s>Reconstitution of PDLIM2 in HRS cell lines inhibits proliferation, blocks NF-κB transcriptional activity and contributes to cHL-specific gene expression.</s><s>In non-Hodgkin B-cell lines, small interfering RNA-mediated PDLIM2 knockdown results in superactivation of TFs NF-κB and AP-1 following phorbol 12-myristate 13-acetate (PMA) stimulation.</s><s>Furthermore, expression of PDLIM2 is lost in anaplastic large cell lymphoma (ALCL) that shares key biological aspects with cHL.</s><s>We conclude that inactivation of PDLIM2 is a recurrent finding in cHL and ALCL, promotes activation of inflammatory signaling pathways and thereby contributes to their pathogenesis.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>2]<ref type="bibr" target="#b2">[3]</ref> The abundant production of inflammatory mediators by HRS cells reflects their highly activated phenotype.</s><s>In line with such a phenotype, HRS cells show constitutive activation of a plethora of transcription factors (TFs) that are physiologically only transiently activated, and that are implicated in cellular activation and immediate-early gene induction.</s><s>]<ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> The mechanisms leading to activation of these TFs in HRS cells are complex and affect various layers of control of respective pathway components. <ref type="bibr" target="#b0">1</ref> These include deleterious mutations of negative regulators of receptor-proximal activation modules, <ref type="bibr" target="#b8">9</ref> of negative regulators of more downstream located signaling components (for example, inhibitor of NF-κB (IκB)α mutations in the NF-κB pathway), <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref> genomic alterations of respective TFs <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref> and the constitutive activation of upstream kinases. <ref type="bibr" target="#b13">14</ref></s><s>The strength and plethora of pathway activation in HRS cells is exceptional among lymphoid malignancies.</s><s>Interestingly, despite their complex transcriptional alterations including long-terminal repeat activation, <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b15">16</ref> HRS cells demonstrate a surprisingly constant phenotype.</s><s>Our recent data on the pivotal role of IRF5 together with NF-κB regarding the orchestration of the HL-specific gene expression program <ref type="bibr" target="#b6">7</ref> suggest that only a limited number of pathogenic events coordinate the cHL phenotype.</s></p><p><s>Given the number of high-level activated TFs in HRS cells involved in immediate-early gene regulation, we postulated that alterations of the ubiquitin system contribute to their simultaneous activation.</s><s>9]<ref type="bibr" target="#b19">[20]</ref> PDLIM2 has been shown to act as ubiquitin E3-ligase inducing inactivation and degradation of TFs. <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b20">21</ref></s><s>In addition, ubiquitin-independent mechanisms of PDLIM2 have been described. <ref type="bibr" target="#b18">19</ref></s><s>By these mechanisms, PDLIM2 controls the activity of TFs, such as NF-κB-p65, STAT1 and STAT3, <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref> that are highly activated in HRS cells.</s><s>Furthermore, alterations of PDLIM2 gene expression have been observed in malignancies, <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref> and the PDLIM2 gene locus in 8p21.3 is in the minimal commonly deleted region in 8p21.3 in several B-cell non-Hodgkin lymphomas. <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27</ref></s><s>ere, we describe an inactivation of the putative ubiquitin E3-ligase PDLIM2 as unifying defect of HRS cells.</s><s>PDLIM2 loss of expression is associated with various mechanisms, including genomic alterations and promoter DNA methylation.</s><s>Functionally, loss of PDLIM2 promotes growth of HRS cells, facilitates the activation of inflammatory TFs and results in deregulation of differentially expressed cHL-associated genes, suggesting a pathogenic role in cHL.</s><s>Furthermore, we demonstrate loss of PDLIM2 expression in anaplastic large cell lymphoma (ALCL) that shares key biological aspects with cHL.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head><p><s>Cell lines and culture conditions HRS (L428, L1236, KM-H2, L591 (EBV + ), U-HO1, SUP-HD1, HDLM-2, L540, L540Cy), pro-B lymphoblastic leukemia (Reh), Burkitt lymphoma (Namalwa, BL-60, BJAB), diffuse large B-cell lymphoma (SU-DHL-4), ALCL (K299, SU-DHL-1, DEL, JB6, all anaplastic lymphoma kinase (ALK) positive; Mac-1, Mac-2A, FE-PD, DL40, all ALK negative), T-cell leukemia-derived (Jurkat, KE-37, Molt-14, H9) and HEK293 cells were cultured as previously described. <ref type="bibr" target="#b27">28</ref></s><s>ells were electroporated in OPTI-MEM I using Gene-Pulser Xcell (Bio-Rad, Munich, Germany) with 950 μF and 0.18 kV (L540Cy, HEK293) or 500 μF and 0.3 kV (Reh, L591).</s><s>Transfection efficiency was determined by pEGFP-N3 (Clontech Laboratories, Mountain View, CA, USA) co-transfection.</s><s>L591 and L540Cy cells were transfected with 40 μg of a pcDNA3-PDLIM2 transcript variant 2 (tv 2) construct along with 10 μg pEGFP-N3.</s><s>GFP + cells were enriched by fluorescence-activated cell sorting.</s><s>Reh cells were transfected with two pSUPER plasmid <ref type="bibr" target="#b28">29</ref> -based siPDLIM2 expression plasmids (each 20 μg) or 40 μg of scrambled small interfering RNA (siRNA) controls along with 10 μg pEGFP-N3 and enriched as previously described. <ref type="bibr" target="#b27">28</ref></s><s>For reporter assays, L591, L540Cy or Reh cells were transfected with 1 μg of 6xκBLuc or 15 μg 5xTRE reporter constructs, together with 50, 25 or 200 ng pRL-TKLuc as internal control.</s><s>Where indicated, cells were additionally transfected with 40 μg pcDNA3-IκBαΔN or pcDNA3-PDLIM2 constructs or controls.</s><s>The ratio of the pRL-TKLuc and 6xκBLuc or 15 μg 5xTRE luciferase activities was determined (Dual luciferase kit; Promega, Mannheim, Germany).</s><s>Where indicated, cells were stimulated with 200 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, Taufkirchen, Germany) or treated with 25 μg/ml cycloheximide (Sigma-Aldrich).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DNA constructs</head><p><s>pcDNA3-IκBαΔN and luciferase constructs pGL3-6xκBLuc and pGL3-5xTRE-TATA (kindly provided by Peter Angel, Heidelberg, Germany) have been previously described. <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b30">31</ref></s><s>PDLIM2 plasmids encoding tv 1 (NM_176871.2;</s><s>1100 bp), variant 2 (NM_021630.4;</s><s>1058 bp) or PDLIM2_ΔLIM were generated by cloning corresponding sequences through 5′ BamHI and 3′ XhoI (tv 1; ΔLIM) or EcoRI (tv 2; varL1236) into pcDNA3.1(+)</s><s>(Invitrogen, Karlsruhe, Germany).</s><s>Primers used for amplification of PDLIM2 variants were PDLIM2 BamHI s 5′-ACACGGATCCTCCACCATGGCGTTGACGGTGGA TGTG-3′ and PDLIM2 XhoI as 5′-ACACGAATTCTCACCAGCTTGGCTGGATG GG-3′ (tv 1) or PDLIM2 EcoRI as 5′-ACACGAATCCTCAGGCCCGAGAGCTG AG-3′ (tv 2).</s><s>PDLIM2_ΔLIM was amplified according to Tanaka et al. <ref type="bibr" target="#b21">22</ref> using primers PDLIM2 BamHI s and PDLIM2_ΔLIM XhoI as 5′-GC CTCGAGTCAGGTGGCCAGGGCCCTG-3′.</s><s>The truncated PDLIM2 variant from L1236 cells was amplified using primers PDLIM2_varL1236 BamHI s 5′-GCGGATCCGCGTTGACGGTGGATGTGGCC-3′ and PDLIM2 EcoRI as.</s><s>The, in comparison with the wt PDLIM2 amplificate, smaller product was excised after gel electrophoresis and cloned into pcDNA3 with N-terminal FLAG.</s><s>Sequences for the siPDLIM2 constructs were selected from the Dharmacon PDLIM2 ON-TARGETplus SMARTpool (J-010731; Dharmacon, Lafayette, CO, USA).</s><s>Target sequences 5′-GGACAGCTCCTTGGAAGTG-3′ or 5′-ACATAATCGTGGCCATCAA-3′ were cloned through BglII and HindIII restriction sites into pSUPER. <ref type="bibr" target="#b28">29</ref></s><s>he scrambled siRNA construct has been previously described. <ref type="bibr" target="#b31">32</ref></s><s>All DNA constructs were verified by sequencing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNA preparation and reverse transcriptase-PCR analyses</head><p><s>Total RNA preparation, complementary DNA synthesis and semiquantitative PCR and real-time quantitative PCR analyses were performed as previously described. <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b27">28</ref></s><s>Primers are listed in Supplementary Table <ref type="table">1</ref>.</s><s>All PCR products were verified by sequencing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of apoptosis and proliferation</head><p><s>The percentage of viable and apoptotic cells was determined by Annexin V-fluorescein isothiocyanate/propidium iodide double staining (Bender MedSystems, Vienna, Austria) and flow cytometry as previously described. <ref type="bibr" target="#b6">7</ref></s><s>roliferation of cells was determined by measurement of [ 3 H]-thymidine incorporation using standard protocols.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blot analyses</head><p><s>Whole-cell and nuclear extract preparation and western blotting were performed as described <ref type="bibr" target="#b4">5</ref> with 30 μg whole-cell or 20 μg nuclear extracts.</s><s>Primary antibodies were: PDLIM2 (sc-79988), IκBα (sc-371; both from Santa Cruz, Heidelberg, Germany), PDLIM2 (ab68220; Abcam, Cambridge, UK) and β-actin (A5316, Sigma-Aldrich).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry</head><p><s>Immunohistochemical stainings of 20 primary cHL, 10 follicular lymphoma, 15 diffuse large B-cell lymphoma and 10 Burkitt lymphoma cases were performed as previously described. <ref type="bibr" target="#b32">33</ref></s><s>Primary antibodies (PDLIM2, PA5-31484, Thermo Scientific, Darmstadt, Germany; PDLIM2, ab68220, Abcam; IκBα, sc-371, Santa Cruz) were applied in a dilution of 1:100 (PDLIM2 antibodies) or 1:500 (IκBα) overnight.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Interphase cytogenetics</head><p><s>Fluorescence in situ hybridization and FICTION (fluorescence immunophenotyping and interphase cytogenetic as a tool for investigation of neoplasia) techniques were used to analyze copy number changes of the PDLIM2 gene in cHL cell lines and primary samples on cryosections from the Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany.</s><s>The anonymized use of these patient samples followed the regulations approved by the institutional review board of the Medical Faculty of the Christian-Albrechts-University Kiel (decision D447/10).</s><s>For FICTION, the procedure included pretreatment with anti-CD30 antibody (BerH2 generated in-house <ref type="bibr" target="#b33">34</ref> ) and detection with Alexa-594-conjugated antibody (Molecular Probes, Leiden, The Netherlands).</s><s>Two hybridization probes were prepared as previously described. <ref type="bibr" target="#b34">35</ref></s><s>They contained DNA from the 157 423 kb large BAC RP11-382J24 (NCBI AC087854.11;</s><s>chr8:22 225 035-22 382 458 genomic position based on the BAC and sequences mapped to the hg19 assembly) containing the SLC39A14 and PPP3CC genes (Invitrogen, GmbH, Darmstadt, Germany) labeled in SpectrumGreen (Abbott/Vysis, Downers Grove, IL, USA) located in the minimally deleted region in B-cell lymphomas 8p21.3 <ref type="bibr">(ref. 27)</ref> ∼ 55 kbp telomeric of the PDLIM2 gene.</s><s>This probe was combined either with the centromeric CEP10 SpectrumAqua probe (assay 1) or the centromeric CEP8 SpectrumOrange probe (assay 2) (both Abbott/Vysis) that served as internal controls.</s><s>Both assays were used independently to the analyzed samples.</s><s>For evaluation, a Zeiss fluorescence microscope (Göttingen, Germany) was used.</s><s>For each case, at least 5 large CD30 + cells were evaluated independently by two observers.</s><s>We estimated the ploidy levels of the analyzed cases by taking median signal numbers for the centromeric probes CEP6, <ref type="bibr">(ref. 9)</ref> CEP10 (this study), CEP16 <ref type="bibr">(ref. 15)</ref> and CEP17. <ref type="bibr" target="#b35">36</ref></s><s>For detection of PDLIM2 deletions, the signal number of the RP11-382J24 probe (PDLIM2) was compared with the ploidy of the respective case separately for both used assays (Supplementary Table <ref type="table">2</ref>).</s><s>Lower number of RP11-382J24 probe signals than the ploidy in at least 30% of the nuclei of the case observed in both assays was indicative for a deletion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bisulfite pyrosequencing</head><p><s>Bisulfite pyrosequencing of two PDLIM2 promoter regions called 'promoter 1' (P1; promoter region of NM_021630) and 'promoter 2' (P2; promoter region of NM_198042, NM_176871) and a previously analyzed region (Qu et al. <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref> called 'pub.</s><s>reg.') was performed according to standard protocols with few modifications. <ref type="bibr" target="#b14">15</ref></s><s>Briefly, genomic DNA was bisulfite converted using the EpiTect Bisulfite Conversion Kit (Qiagen, Hilden, Germany).</s><s>PCR amplification was performed with locus-specific primers with one primer biotinylated at the 5′ end.</s><s>For PDLIM2 amplification reactions, PyroMark PCR Kit (Qiagen) was used.</s><s>After PCR analyses, single strands were prepared followed by a denaturation step at 85 °C for 2 min and final sequencing primer hybridization.</s><s>Pyrosequencing was performed using Pyrosequencer ID and DNA methylation analysis software Pyro Q-CpG 1.0.9 (Biotage, Uppsala, Sweden) that was also used to evaluate the ratio T:C (mC:C) at CpG sites analyzed.</s><s>All assays were optimized and validated using commercially available completely methylated DNA (Millipore, Darmstadt, Germany) and DNA isolated from peripheral blood of 10 healthy male and female controls, respectively.</s><s>The use of human material was approved by the Ethikkommision of the Charité-Universitätsmedizin Berlin and performed in accordance with the Declaration of Helsinki.</s><s>Primers used are listed in Supplementary Table <ref type="table">3</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses of experimental and microarray data</head><p><s>All statistical analyses were done in R v2.9.1 (http://www.r-project.org/) and GraphPad Prism Version 5.0.</s><s>One-sided Welch's t-test was used to analyze real-time quantitative PCR experiments in Figures <ref type="figure" target="#fig_5">4d and 5a</ref>; two-sided Welch's t-test was used to analyze data from proliferation experiments, luciferase assays as well as real-time quantitative PCR experiments.</s><s>Gene expression profiles were determined with Illumina HT-12 v 4.0 Expression BeadChips (Illumina, San Diego, CA, USA).</s><s>Hybridization was performed in duplicates from independent transfection experiments.</s><s>Raw microarray data were background corrected with Illumina's proprietary background correction routine and quantile normalization were applied.</s><s>Subsequently, data were log2 transformed.</s><s>LIMMA was used for determination of significantly differentially expressed genes.</s><s>Listed are all genes with a log2 fold change of at least − /+ 0.5 at 72 h (Supplementary Table <ref type="table">6</ref>).</s><s>Microarray data are available from the Gene Expression Omnibus of the National Center for Biotechnology Information (GSE86845).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Loss of PDLIM2 expression in HRS cell lines</head><p><s>Given the plethora of activated TFs in cHL and a hypothesized involvement of the ubiquitin system in this TF activation, we started our analysis with a literature search on genes associated with the ubiquitin system, combined with the analysis of microarray-based gene expression data of HRS and NH cell lines. <ref type="bibr" target="#b16">17</ref></s><s>One of the most interesting candidates was PDLIM2 that is involved in the control of TF degradation, <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b21">22</ref> and that showed a loss of expression in several of the HRS compared with NH cell lines (data not shown).</s><s>To confirm these data, we analyzed PDLIM2 mRNA and protein expression levels in an extended panel of cell lines (Figure <ref type="figure" target="#fig_0">1</ref>), including various HRS and NH cell lines reflecting different B-cell differentiation stages.</s><s>In contrast to the robust mRNA expression in the analyzed NH cell lines, PDLIM2 mRNA expression was substantially reduced or lost in seven out of nine HRS cell lines (L1236, L591, HDLM-2, L540, L540Cy, U-HO1 and SUP-HD1; Figures <ref type="figure" target="#fig_0">1a and b</ref>).</s><s>Interestingly, maintenance of PDLIM2 expression in L428 and KM-H2 cells correlated with the presence of deleterious IκB mutations. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b36">37</ref></s><s>t the protein level, we confirmed the loss of PDLIM2 expression in most of the HRS cell lines (Figures <ref type="figure" target="#fig_0">1b and c</ref>).</s><s>At least three isoforms of PDLIM2 are known with two major isoforms expressed in the lymphoid compartment. <ref type="bibr" target="#b19">20</ref></s><s>These two isoforms were cloned as controls for PDLIM2 protein expression in immunoblotting experiments (Supplementary Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>In nearly all NH B cell lines, robust expression of PDLIM2 was detectable (Figures <ref type="figure" target="#fig_0">1b and c</ref>), whereas among HRS cell lines PDLIM2 protein expression was only maintained in L428 and KM-H2 cells, for both of which the correlation with a loss of IκBα protein expression was confirmed (Figure <ref type="figure" target="#fig_0">1c</ref>).</s><s>If expressed, the cell lines nearly exclusively expressed PDLIM2 tv 2 (Supplementary Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Interestingly, despite PDLIM2 mRNA expression, L1236 cells virtually lacked PDLIM2 protein expression.</s></p><p><s>Lack of PDLIM2 expression in HRS cells of primary cHL samples Next, we determined PDLIM2 protein expression in primary cHL tissue samples as well as normal lymphoid tissue (Figure <ref type="figure" target="#fig_1">2</ref> and Supplementary Table <ref type="table">4a</ref>).</s><s>We established immunohistochemical analyses with two different antibodies that showed consistent  results.</s><s>In normal lymphoid tissue, PDLIM2 was expressed in virtually all lymphoid cells with however reduced expression levels in germinal center B cells.</s><s>Furthermore, various B-cell non-Hodgkin lymphoma cases including 10 follicular lymphoma, 15 diffuse large B-cell lymphoma and 10 Burkitt lymphoma cases showed PDLIM2 expression in all cases, in the vast majority of them with a strong staining pattern (Supplementary Figure <ref type="figure" target="#fig_1">2</ref>).</s><s>In contrast, among 20 cHL cases of various subtypes with or  without Epstein-Barr virus infection, HRS cells of 19 cases lacked PDLIM2 expression (Figure <ref type="figure" target="#fig_1">2</ref> and Supplementary Table <ref type="table">4a</ref>).</s><s>In all cases, PDLIM2 expression was readily detectable in surrounding cells that served as internal control.</s><s>Only HRS cells of one case expressed PDLIM2, and this was however predominantly observed at the cell membrane (Figure <ref type="figure" target="#fig_1">2g</ref>).</s><s>To investigate a possible correlation with loss of IκBα expression suggested by the cell line analyses, we established immunohistochemical analyses of IκBα using an antibody recognizing the C-terminus of the protein.</s><s>cHL cases lacking IκBα expression due to deleterious truncating mutations would therefore be expected to be negative. <ref type="bibr" target="#b9">10</ref></s><s>In 4 of 20 cHL cases (20%), IκBα protein expression was not detectable, and this is in line with the estimated percentage of deleterious NFKBIA mutations in cHL in other studies; 11 all 4 cases lacked PDLIM2 expression.</s><s>We conclude that loss of PDLIM2 expression is a unifying defect of HRS cells independent of IκB alterations.</s></p><formula xml:id="formula_0">PDLIM2 PARP1 cell line PDLIM2 GAPDH L 4 2 8 U -H O 1 S U P -H D 1 B J A B S U -D H L -4 H D L M -2 RT-PCR WB N a m a l w a B J A B B L -6 0 L 4 2 8 K M -H<label>2</label></formula><p><s>Genomic loss of the PDLIM2 gene locus, aberrant PDLIM2 promoter methylation and altered splicing are associated with loss of PDLIM2 expression in HRS cells To reveal the underlying molecular mechanisms of loss of PDLIM2 expression in cHL cells, we screened for genomic alterations, DNA methylation changes and splicing defects.</s><s>The analysis of previously published SNP-CHIP data <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b37">38</ref> and subsequent fluorescence in situ hybridization analyses (Supplementary Table <ref type="table">2</ref> and Supplementary Figure <ref type="figure" target="#fig_2">3</ref>) indicated deletions of the PDLIM2 locus in 3 out of 4 cHL cell lines, leading us to analyze primary HRS cells for chromosomal losses targeting the PDLIM2 gene.</s><s>For the primary cases we used FICTION analysis that combined anti-CD30 immunophenotyping with the fluorescence in situ hybridization probe for 8p21.3-where</s><s>PDLIM2 is located-and internal centromere controls.</s><s>In 5 out of 20 (25%) cases, we observed a deletion of the PDLIM2 gene in at least 30% of the analyzed HRS cell nuclei (Supplementary Table <ref type="table">2</ref>).</s><s>Remarkably, in one case with a deletion targeting the PDLIM2 locus, in some HRS cells the signal pattern was characteristic for a homozygous deletion.</s><s>In this case, an average of 15% of the HRS cell nuclei lacked the fluorescent probe signal corresponding to the 8p21.3</s><s>region harboring PDLIM2 but showed at least one fluorescent signal for the CEP probes.</s><s>Together, these results are well in line with previous array comparative genomic hybridization studies on primary HRS cells <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref> (for a detailed summary see also Supplementary Table <ref type="table">5</ref>) and suggest that genomic deletions contribute to the loss of PDLIM2 expression in HRS cells.</s><s>An important alternative mechanism of gene silencing in tumor cells is DNA methylation.</s><s>We therefore investigated the methylation status of CpG elements of three different regions in the vicinity of two major PDLIM2 transcription start sites, including one previously published region <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref> (Figure <ref type="figure" target="#fig_2">3a</ref> and Supplementary Figure <ref type="figure" target="#fig_4">4</ref>).</s><s>In HRS cell lines without PDLIM2 expression, two DNA regions (designated as promoter 1 (P1): NM_021630 and promoter 2 (P2): NM_176871) were strongly methylated at the investigated CpG elements (Figure <ref type="figure" target="#fig_2">3a</ref>).</s><s>The same regions were unmethylated in DNA from cells with PDLIM2 expression including NH cell lines, peripheral blood cells from healthy donors or NH mature B cellderived lymphomas, as shown for follicular lymphoma (Figures <ref type="figure" target="#fig_6">3a  and 6e</ref> and Supplementary Figure <ref type="figure" target="#fig_4">4a</ref>).</s><s>In the previously published region (located further upstream in the 5′ region of PDLIM2; designated as pub.</s><s>reg.) that has been associated with PDLIM2 gene methylation in cancer cells, <ref type="bibr" target="#b23">24</ref> we did not observe alterations of PDLIM2 DNA methylation in our samples irrespective of the PDLIM2 expression status (Supplementary Figure <ref type="figure" target="#fig_4">4b</ref>).</s><s>We conclude that aberrant DNA methylation of the P1 and P2 regions is associated with the loss of PDLIM2 expression in HRS cells.</s></p><p><s>Furthermore, in L1236 HRS cells we observed a discrepancy between the-although low-PDLIM2 mRNA but absent protein expression (see Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>We therefore sequenced the L1236 PDLIM2 mRNA to search for sequence alterations (Figure <ref type="figure" target="#fig_2">3b</ref>).</s><s>Apart from expression of PDLIM2 wt transcripts, we revealed in a fraction of transcripts skipping of exon 7 (according to NM_021630.4;</s><s>skipping of 77 bp), resulting in a frameshift and generation of a premature termination codon in exon 8 with a predicted protein size of ∼ 10 kDa smaller than the wt variant and lacking the C-terminally located LIM domain (Figure <ref type="figure" target="#fig_2">3b</ref>), suggesting a loss of function alteration. <ref type="bibr" target="#b21">22</ref></s><s>We cloned this variant (PDLIM2 varL1236) and confirmed a protein size of ∼ 28 kDa by western blot analysis (Figure <ref type="figure" target="#fig_2">3c</ref>).</s><s>Remarkably, by treatment of the cells with cycloheximide we revealed a strongly reduced half-life of this truncated PDLIM2 variant (Figure <ref type="figure" target="#fig_2">3d</ref>), indicating reduced protein stability.</s><s>Sequencing at the DNA level did not show a genomic alteration in L1236 cells (data not shown).</s><s>This splicing variant was not detected in NH cell lines or Epstein-Barr virus-positive lymphoblastoid cells (data not shown).</s><s>Together, our studies indicate that various mechanisms are associated with the loss of PDLIM2 in HRS cells, suggesting a selection pressure for PDLIM2 loss in cHL.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reconstitution of PDLIM2 in HRS cell lines results in reduction of cell growth, inhibition of NF-κB activity and alteration of differentially expressed genes</head><p><s>To investigate the biological consequences of the PDLIM2 loss in HRS cells, we reconstituted PDLIM2 expression in the cell lines L591, L540Cy and SUP-HD1 (Figure <ref type="figure" target="#fig_4">4a</ref> and Supplementary Figure <ref type="figure" target="#fig_5">5a</ref>).</s><s>In these assays, we observed a significant reduction of proliferation following PDLIM2 reconstitution, in L591 cells by ∼ 50% and in L540Cy by ∼ 25% (Figure <ref type="figure" target="#fig_4">4b</ref>).</s><s>We did not observe an alteration of cell viability (data not shown).</s><s>Given the known role of PDLIM2 for termination of NF-κB activity <ref type="bibr" target="#b21">22</ref> and of NF-κB for growth and survival of HRS cells, <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b40">41</ref> we analyzed a possible inhibition of the NF-κB system following PDLIM2 reconstitution in HRS cells using NF-κB-dependent reporter gene studies (Figure <ref type="figure" target="#fig_4">4c</ref> and Supplementary Figure <ref type="figure" target="#fig_5">5b</ref>).</s><s>We included the NF-κB super-repressor IκBαΔN 14 as a positive control.</s><s>As expected, in these cell lines the constitutive NF-κB activity was strongly reduced by IκBαΔN.</s><s>In accordance with an NF-κB inhibitory function, <ref type="bibr" target="#b21">22</ref> PDLIM2 wt also suppressed the NF-κB activity in HRS cell lines.</s><s>In line with a putative loss of function, the truncated PDLIM2 varL1236 was clearly less effective regarding NF-κB inhibition, and a previously characterized loss-of-function ΔLIM variant lacking the LIM domain <ref type="bibr" target="#b21">22</ref> did not alter NF-κB activity (Supplementary Figure <ref type="figure" target="#fig_5">5b</ref>).</s><s>Together, the loss of PDLIM2 contributes to the enhanced NF-κB activity characteristic for HRS cells.</s></p><p><s>To gain insights into PDLIM2-induced transcriptional changes in HRS cells, we performed genome-wide gene expression profiling of L591 cells following PDLIM2 reconstitution by Illumina microarrays.</s><s>In total, 80 genes showed significant expression changes following PDLIM2 reconstitution (Supplementary Table <ref type="table">6</ref>).</s><s>Genes downregulated by PDLIM2 expression included FBXO32, MAK, IL10RA and IER5 (Figure <ref type="figure" target="#fig_4">4d</ref>, upper panel), and their differential gene expression pattern between the HL and NH cell lines (Figure <ref type="figure" target="#fig_4">4d</ref>, lower panel) was verified by PCR analyses.</s><s>These data indicate that the loss of PDLIM2 in HRS cells contributes to the deregulation of HRS cellspecific genes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Superactivation of NF-κB and AP-1 transcriptional activity following downregulation of PDLIM2 in NH cells</head><p><s>Next, we aimed to investigate the consequences of PDLIM2 downregulation on the transcriptional activity of the NF-κB and AP-1 TFs in transformed B lymphoid cells (Figure <ref type="figure" target="#fig_5">5</ref>).</s><s>We transfected Reh and SU-DHL-4 cells with two different PDLIM2-specific siRNAs (Figure <ref type="figure" target="#fig_5">5a</ref> and data not shown).</s><s>Having established the PDLIM2 knockdown, we performed NF-κB reporter assays with these cells.</s><s>As we hypothesized that the effect of PDLIM2 downregulation might be most pronounced following concomitant stimulation of the respective signaling pathways, we included stimulation experiments with the phorbol ester PMA in our reporter gene analyses (Figures <ref type="figure" target="#fig_5">5b and c</ref>).</s><s>As expected, PMA stimulation alone led to a moderate but significant increase of NF-κB reporter activity.</s><s>Importantly, PMA-induced NF-κB stimulation in Reh cells was further increased approximately fivefold following PDLIM2 knockdown (Figure <ref type="figure" target="#fig_5">5b</ref>).</s><s>Similar results were obtained with SU-DHL-4 cells (Figure <ref type="figure" target="#fig_5">5c</ref>).</s><s>Furthermore, we investigated the effect of PDLIM2-modulation on AP-1 reporter activity in Reh cells (Figure <ref type="figure" target="#fig_5">5d</ref>).</s><s>As observed for NF-κB, the PMA-induced AP-1 activity was significantly increased following PDLIM2 knockdown.</s><s>These data indicated that in this experimental setting PDLIM2 controls inducible TF activities and that loss of PDLIM2 enhances the activity of NF-κB and AP-1 TFs.</s><s>]<ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref> We therefore analyzed PDLIM2 expression in ALCL (Figure <ref type="figure" target="#fig_6">6</ref>).</s><s>We revealed a striking downregulation or loss of PDLIM2 expression in ALCL cell lines at the mRNA and protein levels (Figures <ref type="figure" target="#fig_6">6a and b</ref>).</s><s>Similarly, 10 out of 10 ALK-positive and 11 out of 11 ALK-negative primary ALCL cases lacked PDLIM2 protein expression as assessed by immunohistochemistry (Figure <ref type="figure" target="#fig_6">6c</ref> and Supplementary Table <ref type="table">4b</ref>).</s><s>We did not observe chromosomal aberrations of the PDLIM2 gene locus in ALCL (data not shown).</s><s>However, the PDLIM2 locus displayed strong methylation at the P1 and P2 sites in ALCL cell lines lacking PDLIM2 expression (Figure <ref type="figure" target="#fig_6">6d</ref>).</s><s>Furthermore, we observed hypermethylation mainly of the P2 site in the majority of primary ALCL cases analyzed (Figure <ref type="figure" target="#fig_6">6e</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Here we describe and functionally characterize the loss of the putative ubiquitin-E3 ligase PDLIM2 as unifying defect in distinct lymphoma entities, cHL and ALCL.</s><s>PDLIM2 has been linked to tumorigenesis, in particular in colon and breast cancer or HTLV1induced adult T-cell leukemia. <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b45">46</ref></s><s>In these malignancies, PDLIM2 expression levels are consistently reduced, in part because of aberrant DNA methylation. <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref></s><s>Importantly, reconstitution of PDLIM2 reduced the tumor growth, suggesting a tumor suppressor function of PDLIM2. <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b45">46</ref></s><s>However, for most of these malignancies data on PDLIM2 in primary samples are lacking, and cancer cell lines used for these studies display significant PDLIM2 baseline expression levels. <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref></s><s>Our data for cHL and ALCL show the most prominent loss of PDLIM2 expression in malignancies reported so far, and they support a tumor suppressor role of PDLIM2: (1) in most HRS and ALCL cells PDLIM2 expression is undetectable, reflecting a functional PDLIM2 deletion; (2) several mechanisms contribute to PDLIM2 silencing, including aberrant methylation, genomic deletion and altered splicing, all arguing for selective pressure on this gene locus;</s></p><p><s>(3) the biological effects observed in HRS cell lines argue for the functional relevance of lost PDLIM2 expression.</s></p><p><s>In more detail, in line with the work of Tanaka et al., <ref type="bibr" target="#b21">22</ref> we demonstrate that PDLIM2 is ubiquitously expressed in lymphoid cells, with however clearly reduced expression levels in germinal center B cells, as demonstrated in our work.</s><s>In agreement with the expression in lymphoid cells, the analyzed PDLIM2 promoter regions were unmethylated in peripheral mononuclear cells from healthy donors.</s><s>In contrast, PDLIM2 expression was lost and both analyzed PDLIM2 promoter regions were strongly methylated in HRS cell lines.</s><s>Thereby, the already low PDLIM2 expression in germinal center B cells, the putative cells of origin of cHL, 1 might facilitate PDLIM2 silencing in HRS cells.</s><s>Of note, we did not observe an altered methylation in a region previously proposed to be involved in PDLIM2 silencing in cancer cells, <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b24">25</ref> and this might be because of different epigenetic regulations of PDLIM2 between cancer and lymphoid cells, or methodical differences.</s><s>Importantly, the PDLIM2 gene locus is located in a minimal deleted region of 600 kb in 8p21.3 in B-cell non-Hodgkin lymphoma, and TRAIL-R1 and -R2 (tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2) have been suggested as candidate genes of this deletion. <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27</ref></s><s>Our data suggest that PDLIM2 might be a further candidate gene targeted by this deletion.</s><s>Finally, we detected in one HRS cell line a non-DNA-templated altered splicing pattern leading to an instable, C-terminally truncated protein lacking the LIM domain.</s><s>Even though the relevance of this finding for primary cHL remains unclear, similarly truncated mutant constructs-generated for biological studies-lose their putative tumor suppressor function and the ability to ubiquitinate NF-κB-p65. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b23">24</ref></s><s>Together, our data add the loss of PDLIM2 to the list of defects that target inducible signaling pathways in cHL. <ref type="bibr" target="#b0">1</ref> We propose that the major implication of the loss of PDLIM2 expression in HRS cells is the generation of a hyperresponsive cellular background by promoting the sustained activation of TF activities due to disturbed degradation.</s><s>This fits with the observation that HRS cells share hallmark gene expression patterns with highly activated lymphoid cells and that they are characterized by the abundant and constitutive activity of TFs such as NF-κB, AP-1 and STAT that are usually transiently activated and rapidly downregulated following their induction in the physiological context. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b6">7</ref></s><s>Characteristic for HRS cells is thereby, apart from the strength of the activation, the plethora of concomitantly activated TF activities.</s><s>Because of the involvement of PDLIM2 in the termination of TFs including NF-κB, <ref type="bibr" target="#b21">22</ref> STAT factors <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b20">21</ref> and, as suggested by our work, AP-1, the loss of PDLIM2 expression in HRS cells provides a molecular mechanism that contributes to this phenomenon.</s><s>Our data in Reh cells as well as previously published data <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b21">22</ref> indicate that knockdown of PDLIM2 per se is not sufficient for induction of TF activities, that is, the respective signaling pathways need to be stimulated for example by ligand-receptor interactions or constitutive activation of upstream signaling components.</s><s>Up to now, several genomic and molecular defects of such upstream signaling pathway components involved in NF-κB, Janus kinase (JAK)/STAT and AP-1 activation are known in HRS cells. <ref type="bibr" target="#b0">1</ref> Whereas most of these defects target receptor-associated regulatory proteins and rather proximal located kinase modules, the loss of PDLIM2 in HRS cells adds a defect at the far end of the respective TF activation cascades by disabling their nuclear brakes.</s></p><p><s>Functionally, following PDLIM2 reconstitution in HRS cells the biological consequences were weaker than previously demonstrated for, for example, stringent NF-κB inhibition. <ref type="bibr" target="#b40">41</ref></s><s>This is most likely explained by the plethora of upstream defects in the respective signaling cascades in HRS cells <ref type="bibr" target="#b0">1</ref> and the fact that PDLIM2 is certainly not the only factor mediating post-translational modifications of these TFs. <ref type="bibr" target="#b46">47</ref></s><s>Furthermore, experimentally, interfering with TF activities at the far end of their activation cascade is much more sluggish in comparison with direct intervention with super-repressors like IκBαΔN.</s><s>However, HRS cells will provide an ideal tool to further investigate the function and mechanisms of action of PDLIM2 in future studies.</s><s>This is already demonstrated by the identification of PDLIM2 target genes in our study, the function of which in cHL has to be investigated in future studies.</s><s>In addition, future work will be required to elucidate the exact mechanism of how PDLIM2 interferes with TF activation in HRS cells, as ubiquitin-dependent and -independent mechanisms have been described. <ref type="bibr" target="#b18">19</ref></s><s>emarkably, we identified ALCL as a second lymphoid malignancy with a consistent loss of PDLIM2 expression.</s><s>Importantly, ALCL shares biological similarities with cHL, including the loss of cellular identity, <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b42">43</ref> a highly activated phenotype (as exemplified by high-level CD30 expression) <ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b43">44</ref> and activation of AP-1, STAT and NF-κB TFs. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b47">48</ref></s><s>Suppression of PDLIM2 occurs independent of the presence or absence of ALK translocations.</s></p><p><s>Even though ALK activation contributes to the induction of several of the TF activities mentioned above, <ref type="bibr" target="#b48">49</ref> the loss of PDLIM2 expression most likely enhances TF activation in ALCL in a similar manner as described in our work in cHL, and this has to be investigated in future studies.</s></p><p><s>Taken together, we have identified the loss of PDLIM2 as a unifying defect of cHL and ALCL that contributes to the permanent activation of a plethora of key TFs, thereby promoting cellular growth and differential gene regulation.</s><s>These data increase the complexity of molecular and genomic defects already known in these lymphoid malignancies.</s><s>Finally, such defects of the ubiquitin system might offer an explanation for the rather disappointing clinical activity of proteasome inhibitors in cHL. <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b50">51</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p><s>The authors declare no conflict of interest.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Loss of PDLIM2 expression in HRS cell lines.</s><s>(a) PDLIM2 mRNA expression analyses by quantitative (upper panel) and semiquantitative (lower panel) PCR analyses in various HRS and NH cell lines, as indicated.</s><s>(a, upper panel) PDLIM2 mRNA expression was assessed by real-time quantitative PCR (qPCR) and calculated using the 2 − ΔΔCt method.</s><s>Expression in Reh cells was set as 1.</s><s>Error bars denote 95% confidence intervals.</s><s>One out of three independent experiments is shown.</s><s>***Po0.001.</s><s>(a, lower panel) Analysis of PDLIM2 and, as a control, GAPDH mRNA expression in the various cell lines by semiquantitative PCR (sqPCR).</s><s>One of three independent experiments is shown.</s><s>(b) Analysis of PDLIM2 mRNA (upper panel) and protein (lower panel) expression in HRS (L428, HDLM-2, U-HO1, SUP-HD1) and NH (BJAB, SU-DHL-4) cell lines, as indicated.</s><s>Expression of GAPDH and PARP1 are shown as controls.</s><s>One of three independent experiments is shown.</s><s>WB, western blot analysis.</s><s>(c) Analysis of PDLIM2 and IκBα protein expression in various cell lines, as indicated.</s><s>Nuclear extracts were analyzed for PDLIM2 (upper panel), and whole-cell extracts for IκBα (lower panel) protein expression; expression of PARP1 and β-actin are shown as controls.</s><s>One of four independent experiments is shown.</s><s>Note that L428 and KM-H2 cells lack IκBα protein expression because of deleterious NFKBIA mutations or deletions. 10</s></p></div></figDesc><graphic coords="3,364.61,171.05,160.10,283.10" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. HRS cells of primary classical HL cases rarely express PDLIM2 and show a recurrent loss of IκBα protein expression.</s><s>(a, b) Naive mantle zone B cells present an intense PDLIM2 protein expression, whereas PDLIM2 expression is weak in germinal center B cells (a, × 100; b, × 200).</s><s>(c, d) Representative cHL mixed cellularity case with lost PDLIM2 expression (c, × 200, insert, × 400) and lost IκBα expression (d, × 200, insert, × 400).</s><s>(e, f) Representative cHL nodular sclerosis case showing lost PDLIM2 expression (e, × 200, insert, × 400).</s><s>This case shows weak IκBα protein expression in the HRS cells (f, × 200, insert, × 400).</s><s>(g, h) In this exceptional cHL mixed cellularity case a membrane-bound PDLIM2 expression pattern occurred (g, × 200, insert, × 400).</s><s>The IκBα protein expression was typically weak in the HRS cells of this case (h, × 200, insert, × 400).</s><s>For all PDLIM2 stainings shown in this figure, a rabbit anti-PDLIM2 antibody was used.</s></p></div></figDesc><graphic coords="4,111.86,59.30,362.04,599.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3.</s><s>DNA methylation of the PDLIM2 promoters in HRS cell lines; altered splicing of PDLIM2 mRNA in L1236 cells.</s><s>(a, upper panel) Overview of the regions analyzed (amplicons) for DNA methylation.</s><s>P1, amplicon of this region corresponds to the region of the transcription start site (TSS) of the PDLIM2 transcript variant 2 (NM_021630); P2, amplicon of this region corresponds to the region of the TSS of the PDLIM2 transcript variant 1 (NM_176871); pub.</s><s>reg., a region previously analyzed for methylation. 24,25</s><s>The percentage GC content of the DNA is shown in five-base windows.</s><s>The exon-intron structures of the PDLIM2 transcript variants are diagrammed underneath.</s><s>(a, lower panel) Result of bisulfite pyrosequencing in various cell lines, as indicated.</s><s>The percentage of DNA methylation for each individual CpG element in each amplicon is represented by a color code (red, CpG site fully methylated (100%); green, CpG site fully unmethylated (0%)).</s><s>As controls, commercially available completely methylated DNA (mean methyl.</s><s>control) and unmethylated pooled DNA extracted from peripheral blood (mean pool pB) were included.</s><s>(b) PDLIM2 altered splicing in L1236 cells.</s><s>(b, left panel) mRNA sequence of a PDLIM2 transcript amplified in L1236 cells.</s><s>Shown is the PDLIM2 mRNA sequence with skipping of exon 7 (end of exon 6 is underlined in black, beginning of exon 8 is underlined in red; according to NM_021630.4) that results in a reading frame shift and generation of a premature STOP (TGA, marked in red).</s><s>The wild-type (wt) STOP codon is marked in bold black.</s><s>(b, right panel) Structure of wt PDLIM2 and the predicted truncated L1236 variant that results in a C-terminally truncated protein with deletion of the LIM domain (black box, protein sequence out of frame).</s><s>AA numbers of the proteins are indicated.</s><s>(c) PDLIM2 protein variants.</s><s>HEK293 cells were transfected with empty plasmid (Mock) as a control, or plasmids encoding PDLIM2 tv2, the L1236 splicing variant (varL1236) or a C-terminally truncated version lacking the LIM domain.<ref type="bibr" target="#b21">22</ref></s><s>Western blot (WB) was performed using antibody ab68220.</s><s>Expression of PARP1 is shown as control.</s><s>(d) The PDLIM2 L1236 splicing variant is instable.</s><s>HEK293 cells were transfected with control plasmid ( − ) or plasmids encoding PDLIM2 tv2 or the L1236 splicing variant (PDLIM2 varL1236).</s><s>At 48 h after transfection, cells were treated with cycloheximide (CHX).</s><s>At the indicated times, whole-cell lysates were prepared and analyzed for expression of the respective PDLIM2 proteins.</s><s>Expression of PARP1 was analyzed as a control.</s><s>One of three independent experiments is shown.</s><s>Note that the expression level of PDLIM2 varL1236 rapidly decreases following CHX treatment, whereas the expression level of PDLIM2 tv 2 remains stable even after 6 h of CHX treatment.</s></p></div></figDesc><graphic coords="5,97.01,165.29,434.90,375.14" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. PDLIM2 reconstitution in HRS cell lines reduces proliferation and suppresses NF-κB transcriptional activity; analysis of PDLIM2 regulated, differentially expressed genes.</s><s>(a) The HRS cell lines L591 and L540Cy were transiently transfected with empty plasmid as a control (Mock) or PDLIM2 (tv 2) expression plasmid (PDLIM2) along with a pEGFP expression plasmid.</s><s>At 48 h after transfection, transfected GFP + cells were enriched and protein expression of PDLIM2 and, as a control, β-actin, was analyzed by western blot (WB).</s><s>Reh cells with and Mac-2A cells without PDLIM2 expression (see also Figure6) as well as empty plasmid (Mock) or PDLIM2-transfected HEK293 cells were included as controls.</s><s>(b) PDLIM2 reconstitution reduces proliferation of HRS cell lines.</s><s>Cells were transfected and enriched as described in (a).</s><s>At 24, 48 and 72 h after enrichment, cells were pulsed with 1 μCi[ 3 H]-thymidine per well for a further 20 h, and [ 3 H]-thymidine incorporation was determined.</s><s>c.p.m., counts per min.</s><s>(c) PDLIM2 reconstitution suppresses NF-κB transcriptional activity in HRS cell lines.</s><s>(c, upper panel) pGL3-basic or 6xκBLuc-constructs were transfected into HRS cell lines together with empty plasmid (Mock; filled bars) or PDLIM2 (gray bars) or IκBαΔN (open bars) expression constructs.</s><s>Luciferase activity is shown as fold activation compared with pGL3-basic (set 1).</s><s>Data are represented as mean ± s.d.</s><s>(c, lower panel) Expression of PDLIM2, IκBαΔN and, as a control, β-actin in transfected cells was analyzed by WB.</s><s>Note that IκBαΔN is significantly smaller than full-length IκBα.</s><s>One out of five independent experiments is shown.</s><s>*P o0.05; **Po0.01;</s><s>***P o0.001.</s><s>(d) Analysis of PDLIM2-regulated genes in L591 HRS cells.</s><s>L591 cells were transfected and enriched as described in (a).</s><s>(d, upper panel) FBXO32, IL10RA, MAK and IER5 mRNA expression was assessed by real-time PCR and calculated using the 2 − ΔΔCt method.</s><s>Expression in Mock-transfected cells was set as 1.</s><s>Error bars denote 95% confidence intervals.</s><s>One out of three independent experiments in shown.</s><s>**P o0.01; ***Po 0.001.</s><s>(d, lower panel) Analysis of FBXO32, IL10RA, MAK, IER5 and, as a control, GAPDH mRNA expression in the various cell lines by reverse transcriptase-PCR (RT-PCR).</s><s>One of three independent experiments is shown.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. Knockdown of PDLIM2 in NH cells results in NF-κB and AP-1 superactivation.</s><s>(a) Knockdown of PDLIM2 in Reh cells.</s><s>Reh cells were transfected with control (siCTL) or a combination of two PDLIM2-specific siRNA (siPDLIM2 #1+#2/siPDLIM2) constructs, and enriched transfected cells were analyzed for PDLIM2 mRNA (left) and protein (right) expression.</s><s>(a, left) PDLIM2 mRNA expression was assessed by realtime PCR and calculated using the 2 − ΔΔCt method.</s><s>Expression in control-transfected Reh cells was set as 1.</s><s>Error bars denote 95% confidence intervals.</s><s>***P o0.001.</s><s>(a, right) Analysis of PDLIM2 protein expression in siCTL-and siPDLIM2-transfected Reh cells.</s><s>Whole-cell extracts were analyzed for protein expression of PDLIM2 and, as a control, β-actin.</s><s>Untransfected Reh (positive control) and L591 (negative control) cells as well as Mock-or PDLIM2-transfected HEK293 cells are shown as controls.</s><s>(b) Reh cells were transiently transfected with pGL3-basic or 6xκBLucreporter gene constructs together with control (siCTL) or a combination of two PDLIM2-specific siRNA (siPDLIM2 #1+#2 / siPDLIM2) constructs.</s><s>At 48 h after transfection, cells were left untreated or treated twice with PMA.</s><s>Thereafter, cells were analyzed for luciferase activity.</s><s>Luciferase activity is shown as fold activation compared with pGL3-basic-and siCTL-transfected and unstimulated cells (set 1).</s><s>Data are represented as mean ± s.d.</s><s>One of four independent experiments is shown.</s><s>***Po 0.001.</s><s>(c) SU-DHL-4 cells were transiently transfected and analyzed as described in (c).</s><s>One of three independent experiments is shown.</s><s>*P o0.05; **Po 0.01; ***Po 0.001.</s><s>(d) Reh cells were transiently transfected with pGL3-basic or 5xTRE-Luc-(AP-1) reporter gene constructs together with control (siCTL) or a combination of two PDLIM2-specific siRNA (siPDLIM2 #1+#2/siPDLIM2) constructs.</s><s>At 48 h after transfection, cells were left untreated or treated twice with PMA.</s><s>Thereafter, cells were analyzed for luciferase activity.</s><s>Luciferase activity is shown as fold activation compared with pGL3-basic-and siCTL-transfected and unstimulated cells (set 1).</s><s>Data are represented as mean ± s.d.</s><s>One of four independent experiments is shown.</s><s>***P o0.001.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Loss of PDLIM2 expression in ALCL.</s><s>(a) PDLIM2 mRNA expression analyses by quantitative (upper panel) and semi-quantitative (lower panel) PCR analyses in ALK-positive (K299, SU-DHL-1, DEL, JB6) and ALK-negative (FE-PD, Mac-1, Mac-2A, DL40) ALCL as well as T-cell leukemiaderived (Jurkat, KE-37, Molt-14, H9) control cell lines.</s><s>(a, upper panel) PDLIM2 mRNA expression was assessed by real-time quantitative PCR and calculated using the 2 − ΔΔCt method.</s><s>Expression in Jurkat cells was set as 1.</s><s>Error bars denote 95% confidence intervals.</s><s>One out of three independent experiments in shown.</s><s>***P o0.001.</s><s>(a, lower panel) Analysis of PDLIM2 and, as a control, GAPDH mRNA expression by sqPCR.</s><s>One of three independent experiments is shown.</s><s>(b) Analysis of PDLIM2 and IκBα protein expression in the various cell lines.</s><s>Whole-cell extracts were analyzed for protein expression of PDLIM2 (upper panel), IκBα (center) and, as a control, β-actin (lower panel).</s><s>One of four independent experiments is shown.</s><s>(c) Lack of PDLIM2 expression in primary ALCL.</s><s>Representative immunohistochemical (IHC) stainings of one ALK-positive (left) and one ALK-negative (right) ALCL case.</s><s>Note that the large ALCL cells lack PDLIM2 protein expression, whereas infiltrating hematopoietic cells express PDLIM2.</s><s>(d) Methylation of the PDLIM2 promoter regions in ALCL cell lines.</s><s>Result of bisulfite pyrosequencing in various cell lines, as indicated; for the analyzed regions refer to Figure 3a.</s><s>The percentage of DNA methylation for each individual CpG element in each amplicon is represented by a color code (red, CpG site fully methylated (100%), green, CpG site fully unmethylated (0%)).As controls, commercially available completely methylated DNA (mean methyl.</s><s>control) and unmethylated pooled DNA extracted from peripheral blood (mean pool pb) were included.</s><s>(e) Methylation of the PDLIM2 promoter regions in primary ALK-positive ALCL analyzed by bisulfite pyrosequencing and follicular lymphoma (FL) samples analyzed by whole methylome sequencing.<ref type="bibr" target="#b51">52</ref> Results are depicted as described in (d).</s><s>NA, data not available; TCC, tumor cell content.</s></p></div></figDesc><graphic coords="10,49.01,96.17,488.18,349.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>70 30 22,440,000 22,445,000 22,450,000 22,455,000</head><label></label><figDesc></figDesc><table><row><cell></cell><cell cols="3">chr8 (p21.3)</cell><cell cols="2">23.2</cell><cell>8p23.1</cell><cell>8p22</cell><cell cols="2">21.3</cell><cell>21.2</cell><cell>8p12</cell><cell>8q12.1</cell><cell>12.3</cell><cell>8q24.3</cell></row><row><cell cols="2">pub. reg.</cell><cell cols="2">P1</cell><cell>P2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">promoter 1: NM_021630</cell><cell>promoter 2: NM_176871</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Sample ID</cell><cell cols="2">CpG 1 CpG 2</cell><cell cols="2">CpG 3</cell><cell>CpG 4</cell><cell>CpG 5 CpG 6 CpG 7</cell><cell>CpG 1 CpG 2</cell><cell>CpG 3</cell><cell>CpG 4</cell><cell>CpG 5</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>L428</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>L1236</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>HRS NH</cell><cell cols="2">KM-H2 L591 HDLM-2 L540 L540Cy Reh Namalwa</cell><cell></cell><cell></cell><cell></cell><cell>DNA methylation</cell><cell>in %</cell><cell>0 100</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>BJAB</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">mean methyl cont.</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">mean pool pb</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">Exon 6 Exon 8</cell></row><row><cell cols="11">..CCTGTCCTACTCAGGCCGCCCTGGAAGCCGACAGCATGGACTCGGAAG</cell></row><row><cell cols="11">GGGGAAGCCTCCTCCTGGACGAGGACTCGGAAGTCTTCAAGATGCTGCAG</cell><cell>1</cell><cell>7 8</cell><cell>2 7 9</cell><cell>3 5 2</cell></row><row><cell cols="11">GAAAATCGCGAGGGACGGGCGGCCCCCCGACAGTCCAGCTCCTTTCGGCT CTTGCAGGAAGCCCTGGAGGCTGAGGAGAGAGGTGGCACGCCAGCCTTCT</cell><cell>PDLIM2 wt</cell><cell>PDZ</cell><cell>LIM</cell></row><row><cell cols="11">TGCCCAGCTCACTGAGCCCCCAGTCCTCCCTGCCCGCCTCCAGGGCCCTG GCCACCCCTCCCAAGCTCCACACTTGTGAGAAGTGCAGTACCAGCATCGC GAACCAGGCTGTGCGCATCCAGGAGGGCCGGTACCGCCACCCCGGCTGCT</cell><cell>PDLIM2 var L1236</cell><cell>1</cell><cell>PDZ</cell><cell>78</cell><cell>179</cell><cell>224</cell></row><row><cell cols="11">ACACCTGTGCCGACTGTGGGCTGAACCTGAAGATGCGCGGGCACTTCTGG</cell></row><row><cell cols="11">GTGGGTGACGAGCTGTACTGTGAGAAGCATGCCCGCCAGCGCTACTCCGC</cell></row><row><cell cols="7">ACCTGCCACCCTCAGCTCTCGGGCCTGA..</cell><cell></cell><cell></cell><cell></cell></row><row><cell>cell type</cell><cell cols="2">M o c k t v 2</cell><cell cols="2">Δ L I M v a r L 1 2 3 6</cell><cell></cell><cell></cell><cell></cell><cell cols="3">CHX HEK293</cell><cell>0.5</cell><cell>1 2 3 4 5 6 PDLIM2 tv2</cell><cell>0.5</cell><cell>1 PDLIM2 varL1236 2 3 4 5 6</cell><cell>hours</cell></row><row><cell>PDLIM2 tv2 PDLIM2 varL1236</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>PDLIM2 ΔLIM</cell><cell cols="4">PDLIM2 tv2 PDLIM2 varL1236</cell><cell>36 kDa 28 kDa</cell></row><row><cell>PARP1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">PARP1</cell></row></table><note><p><s>chr8:</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Leukemia (2017) 602 -613</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© The Author(s) 2017Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p><s>We thank Simone Kressmann and Brigitte Wollert-Wulf as well as the technical staff of the molecular cytogenetics and epigenetics laboratories at the Institute of Human Genetics in Kiel for excellent technical assistance.</s><s>This work was supported in part by grants from the Deutsche Forschungsgemeinschaft to SM, MJ, GL and SH, the Experimental and Clinical Research Center, a joint cooperation between the Charité-Universitätsmedizin Berlin and the MDC as well as the German Cancer Consortium (DKTK).</s><s>MG was supported by the FEBS 'Long Term Fellowship' and 'Support for International Mobility of Scientists' fellowship of the Polish Ministry of Science and Higher Education.</s><s>RS and WK are supported by the KinderKrebsInitiative Buchholz/Holm-Seppensen and JR by the Dr Werner Jackstädt Foundation in the framework of a Junior Excellence Research Group (S134-10.100).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Küppers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Engert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hansmann</surname></persName>
		</author>
		<author>
			<persName><surname>Hodgkin Lymphoma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="3439" to="3447" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Molecular pathogenesis of Hodgkin&apos;s lymphoma: increasing evidence of the importance of the microenvironment</title>
		<author>
			<persName><forename type="first">C</forename><surname>Steidl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Connors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1812" to="1826" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&apos;s lymphoma</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Ansell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lesokhin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Borrello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Halwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gutierrez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="311" to="319" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin&apos;s disease tumor cells</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Bargou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Emmerich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Krappmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bommert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Mapara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Arnold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="2961" to="2969" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mathas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Anagnostopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Krappmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jundt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="4104" to="4113" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">IL-21 is expressed in Hodgkin lymphoma and activates STAT5; evidence that activated STAT5 is required for Hodgkin lymphomagenesis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Scheeren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Diehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Smit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Beaumont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Naspetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Bende</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="4706" to="4715" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kreher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Bouhlel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cauchy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lamprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="E4513" to="E4522" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">STAT3 is constitutively activated in Hodgkin cell lines</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Holtick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vockerodt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ahmadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Haier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Behrmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="762" to="770" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hansmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bohle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Martin-Subero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mechtersheimer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">206</biblScope>
			<biblScope unit="page" from="981" to="989" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Emmerich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Demel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Foss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jundt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="3129" to="3134" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases</title>
		<author>
			<persName><forename type="first">A</forename><surname>Lake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Shield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cordano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Chui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Osborne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Crae</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="1334" to="1342" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Hodgkin&apos;s lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2</title>
		<author>
			<persName><forename type="first">S</forename><surname>Joos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Granzow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Holtgreve-Grez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Harder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Martin-Subero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="489" to="495" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Detection of genomic imbalances in microdissected Hodgkin-and Reed-Sternberg cells of classical Hodgkin lymphoma by array based comparative genomic hybridization</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Martin-Subero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gesk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hüsken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giefing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nagel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1318" to="1326" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells</title>
		<author>
			<persName><forename type="first">D</forename><surname>Krappmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Emmerich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kordes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Scharschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dörken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Scheidereit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="943" to="953" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma</title>
		<author>
			<persName><forename type="first">B</forename><surname>Lamprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kreher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lenze</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="571" to="579" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Oncoexaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Babaian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Romanish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gagnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Karimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Steidl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2542" to="2546" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas</title>
		<author>
			<persName><forename type="first">K</forename><surname>Köchert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ullrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kreher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Aster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kitagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jöhrens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1831" to="1840" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Pdlim2, a novel PDZ-LIM domain protein, interacts with alpha-actinins and filamin A</title>
		<author>
			<persName><forename type="first">M</forename><surname>Torrado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">V</forename><surname>Senatorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Trivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Fariss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Tomarev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Invest Ophthalmol Vis Sci</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="3955" to="3963" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Grusby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="729" to="736" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses anchorageindependent growth</title>
		<author>
			<persName><forename type="first">G</forename><surname>Loughran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Healy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Kiely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Huigsloot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Kedersha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Biol Cell</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1811" to="1822" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">PDLIM2 inhibits T helper 17 cell development and granulomatous inflammation through degradation of STAT3</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Muromoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sekine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Grusby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Signal</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">85</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Grusby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kaisho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="584" to="591" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Oncovirus Kaposi sarcoma herpesvirus (KSHV) represses tumor suppressor PDLIM2 to persistently activate nuclear factor kappaB (NF-kappaB) and STAT3 transcription factors for tumorigenesis and tumor maintenance</title>
		<author>
			<persName><forename type="first">F</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Qu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page" from="7362" to="7368" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiao</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="11786" to="11792" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">DNA methylationdependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Grusby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Smithgall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1766" to="1772" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Martinez-Climent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vizcarra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blesa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Marugan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Benet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="3479" to="3482" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rubio-Moscardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blesa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mestre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Balasas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="3214" to="3222" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Repeat-element driven activation of proto-oncogenes in human malignancies</title>
		<author>
			<persName><forename type="first">B</forename><surname>Lamprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bonifer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mathas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Cycle</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="4276" to="4281" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">A system for stable expression of short interfering RNAs in mammalian cells</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Brummelkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bernards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Agami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="page" from="550" to="553" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Two distinct phospholipases C of Listeria monocytogenes induce ceramide generation, nuclear factor-kappa B activation, and E-selectin expression in human endothelial cells</title>
		<author>
			<persName><forename type="first">N</forename><surname>Schwarzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Seybold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Parida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Fuhrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krull</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="3010" to="3018" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Peterziel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Danner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barbus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Radlwimmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="426" to="439" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Janz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Truss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wollert-Wulf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mathas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jöhrens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="2536" to="2539" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert&apos;s lymphoma nowadays?</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Agostinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Korkolopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Marafioti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Histopathology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1173" to="1182" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope</title>
		<author>
			<persName><forename type="first">R</forename><surname>Schwarting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gerdes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dürkop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Falini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pileri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="1678" to="1689" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">FISH and FICTION to detect chromosomal aberrations in lymphomas</title>
		<author>
			<persName><forename type="first">M</forename><surname>Giefing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods Mol Biol</title>
		<imprint>
			<biblScope unit="volume">971</biblScope>
			<biblScope unit="page" from="227" to="244" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Otto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giefing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Massow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Vater</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gesk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schlesner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="702" to="708" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Emmerich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Theurich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haeffker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Vry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Döhner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">201</biblScope>
			<biblScope unit="page" from="413" to="420" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Giefing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Winoto-Morbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sosna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Döring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Küppers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e84928</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Genomewide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome</title>
		<author>
			<persName><forename type="first">C</forename><surname>Steidl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Telenius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Farinha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Barclay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boyle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="418" to="427" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Slovak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bedell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Estrine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Nowak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Delioukina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="3443" to="3454" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Nuclear factor kappaB-dependent gene expression profiling of Hodgkin&apos;s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lemke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Anagnostopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Krappmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mathas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="page" from="605" to="617" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features</title>
		<author>
			<persName><forename type="first">H</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Foss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dürkop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Marafioti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Delsol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pulford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="3681" to="3695" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling</title>
		<author>
			<persName><forename type="first">I</forename><surname>Bonzheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Geissinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zettl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="3358" to="3360" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Eckerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Brune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Döring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tiacci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bohle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sundstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2129" to="2138" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mathas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jöhrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Joos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Janz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="4287" to="4293" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation</title>
		<author>
			<persName><forename type="first">P</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Grusby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="4370" to="4380" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Posttranslational modifications of NF-kap-paB: another layer of regulation for NF-kappaB signaling pathway</title>
		<author>
			<persName><forename type="first">B</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">D</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lamb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Signal</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1282" to="1290" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Crescenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Abate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lasorsa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tabbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gaudiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chiesa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="516" to="532" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The anaplastic lymphoma kinase in the pathogenesis of cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Chiarle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Voena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ambrogio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Piva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Inghirami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="11" to="23" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Niedzwiecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Canellos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Bartlett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1313" to="1319" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Younes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fayad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="1731" to="1732" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kretzmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Bernhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Weniger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Bergmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1316" to="1325" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article&apos;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material</title>
		<imprint/>
	</monogr>
	<note>To view a copy of this license, visit http://</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
